Stroke Clinical Trials 2026 — 580 Active Studies, 44 Phase 3 Programs

The stroke clinical trial landscape in 2026

Stroke remains one of the largest unmet medical needs in neurology. Despite decades of research, IV tPA and mechanical thrombectomy remain the only acute treatments with proven efficacy, and the treatment window for most patients remains narrow. This gap drives substantial ongoing trial activity across neuroprotection, extended reperfusion windows, hemorrhagic stroke management, and functional recovery.

Stroke trials are often large, multi-site, and operationally complex — making competitive landscape monitoring critical for sponsors managing enrollment against comparable studies.

Acute ischemic stroke: extending treatment windows

The biggest unmet need in ischemic stroke is extending the treatment window for thrombectomy and thrombolysis. Most major stroke centers globally now perform thrombectomy up to 24 hours in selected patients following DAWN and DEFUSE 3, but the optimal patient selection criteria continue to be refined. Current trials focus on:

• Late-window thrombectomy: refining imaging selection criteria (penumbra vs. core ratio)
• Tenecteplase vs. alteplase: Phase 3 non-inferiority trials for IV thrombolysis
• Dual antiplatelet therapy (DAPT) timing for minor stroke and high-risk TIA
• Direct oral anticoagulants (DOACs) in cardioembolic stroke: optimal start time
• MRI-guided late thrombolysis in patients with unknown time of onset ("wake-up stroke")

Neuroprotection: the field's biggest challenge

Neuroprotection remains the holy grail of stroke therapy — hundreds of compounds have failed in clinical trials after showing promise in animal models. Despite this history, new mechanisms continue to enter trials:

• Hypothermia (selective brain cooling devices, pharmacological hypothermia)
• Anti-inflammatory strategies: IL-1 receptor antagonists, complement inhibitors
• Mitochondrial protection: edaravone formulations, succinate analogs
• Stem cell and cell therapy approaches for subacute stroke
• Remote ischemic conditioning (limb ischemia-reperfusion as neuroprotective signal)

Intracerebral hemorrhage (ICH): an undertreated area

Hemorrhagic stroke has fewer proven treatments than ischemic stroke, making it an active area for new trials:

• Rapid blood pressure reduction: refined targets and treatment protocols (INTERACT3)
• Factor Xa inhibitor reversal: andexanet alfa real-world and expanded trials
• Minimally invasive hematoma evacuation: catheter-directed surgery vs. standard care
• Anti-inflammatory interventions to reduce perihematomal edema
• Coagulopathy reversal timing in anticoagulation-related ICH

Stroke recovery and neurorehabilitation

Post-stroke recovery represents a large and growing segment of stroke trial activity. The unmet need is enormous — only 25% of stroke survivors recover full independence. Active trial areas include:

• Noninvasive brain stimulation: transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS) for motor recovery
• Constraint-induced movement therapy (CIMT) protocol optimization
• Robot-assisted rehabilitation for upper extremity function
• Pharmacological augmentation of rehabilitation: amphetamines, SSRIs, nortriptyline (FOCUS trial follow-up)
• Stem cell therapy for chronic stroke deficits: multiple Phase 1/2 programs
• Vagus nerve stimulation (VNS) paired with rehabilitation: FDA-cleared for ischemic stroke arm weakness

Secondary stroke prevention

With 25% of strokes being recurrent, secondary prevention generates ongoing trial activity:

• Cryptogenic stroke: patent foramen ovale (PFO) closure long-term outcomes and new anticoagulation strategies
• Colchicine and anti-inflammatory therapy for recurrent stroke in atherosclerosis
• Inclisiran and other novel lipid-lowering agents in stroke secondary prevention
• Blood pressure variability: targeting fluctuation rather than mean BP level

Who monitors stroke clinical trials?

• Neurology and vascular neurology pharma teams monitoring competitor trials in acute stroke, recovery, and prevention
• CROs and site management organizations tracking enrollment competition across stroke trials at overlapping sites
• Medical device companies with neurointerventional or rehabilitation device programs
• Academic stroke researchers reviewing what Phase 2 programs are succeeding before designing new studies
• Stroke foundation and advocacy organizations tracking the pipeline for patient communication

Key Phase 3 stroke trials (2025–2026)

The 2026 stroke Phase 3 landscape spans four broad areas: acute thrombolysis optimization, hemorrhagic stroke management, secondary prevention, and neurorehabilitation augmentation. Illustrative active programs:

Program / Drug	Sponsor	Area	Key Question
Tenecteplase vs. alteplase	Multiple (academic, NINDS, HRC)	Acute ischemic stroke	Non-inferiority vs. tPA; single bolus vs. infusion
Andexanet alfa (Andexxa)	AstraZeneca / Alexion	ICH — anticoagulant reversal	Factor Xa reversal outcomes in anticoagulation-related ICH (ANNEXA-I)
Minimally invasive ICH evacuation	Multiple (ENRICH, INVEST)	ICH — surgical	Catheter-directed vs. standard care for lobar/basal ganglia ICH
Inclisiran	Novartis	Secondary prevention	siRNA PCSK9 inhibitor; twice-yearly dosing vs. statin in cerebrovascular outcomes
Colchicine (CONVINCE)	Academic (University of Edinburgh)	Secondary prevention	Anti-inflammatory secondary stroke prevention after non-cardioembolic stroke
Vagus nerve stimulation (VNS)	MicroTransponder / LivaNova	Stroke recovery	Paired VNS + rehabilitation for chronic stroke arm weakness (FDA-cleared)

Tenecteplase vs. alteplase: the biggest acute stroke trial question in 2026

The potential replacement of alteplase (tPA) with tenecteplase for acute ischemic stroke thrombolysis represents one of the most commercially and clinically significant Phase 3 questions in stroke. Tenecteplase offers practical advantages: it is given as a single IV bolus in 5–10 seconds versus alteplase's 1-hour infusion. This simplifies drip-and-ship transfers to thrombectomy centers and reduces the risk of tPA extravasation from long infusion lines.

Multiple major trials have reported results or are enrolling in 2026. The AcT trial in Canada showed non-inferiority; NORTEST-2 and other European programs added confirmatory data. Regulatory submissions are at different stages globally, but tenecteplase has effectively replaced alteplase in several healthcare systems as clinical practice moves ahead of formal approval in some markets. For sponsors developing devices or drugs that interact with IV thrombolysis, understanding the tenecteplase transition is critical competitive intelligence.

Related neurology clinical trial monitors

• Coronary artery disease clinical trials — overlapping atherosclerosis, anti-thrombotic, and cardiovascular risk reduction programs
• Alzheimer's clinical trials — overlapping neuroinflammation and vascular dementia programs
• Parkinson's disease clinical trials — related neurodegeneration and neuroprotection approaches
• Multiple sclerosis clinical trials — shared neurology infrastructure and CNS drug development approaches